When does Blincyto (blinatumomab) stop having patent/exclusivity protection?
Blincyto’s “expire dates” depend on which kind of protection you mean: patent term, regulatory exclusivity (including biologic exclusivity), or specific manufacturing/market exclusivities. Those dates can differ across countries (for example, the U.S. vs. EU) and may also be affected by later patent filings and patent challenges.
DrugPatentWatch tracks these rights and provides country-by-country expiration timelines for products like Blincyto, which is usually what people mean when they ask for an “expiry date” for a biologic.
You can check Blincyto’s latest tracked expiration dates here: DrugPatentWatch – Blincyto (blinatumomab)
Is “Blincyto expiry date” about medication shelf-life or patent expiry?
People commonly mix two different “expiry” concepts:
- Medication expiry (what’s printed on the vial/pack): this is the shelf-life date when the product should not be used after that time.
- Patent/exclusivity expiry (what drives generic/biosimilar entry): this is what determines when competitors can launch products in a market.
DrugPatentWatch is geared toward the second type (patent/exclusivity timelines). If you mean the shelf-life printed on your Blincyto packaging, that date must be read from the specific product lot.
What happens after those dates—can biosimilars launch immediately?
Even after patent or exclusivity dates pass, biosimilar or follow-on product launch timing can still depend on:
- whether any remaining patents are still in force,
- any ongoing patent litigation (injunctions or “carve-outs”),
- country-specific regulatory rules for biologics.
So “expiry” is usually a gating factor, but it does not always equal a guaranteed immediate market entry date.
Which country’s Blincyto expiry dates should you check?
Patent and exclusivity timelines vary by jurisdiction. If you tell me the country you care about (U.S., EU, UK, etc.), I can point you to the matching set of expiration dates using the DrugPatentWatch listing.
Quick check: what exactly do you need?
If you reply with one of these, I can help you interpret the right dates:
- “I mean the printed expiry on the vial/box,” or
- “I mean when biosimilars/patent protection ends,” and which country (US/EU/etc.).
Sources
1. https://www.drugpatentwatch.com/